Published on 20 Jun 2024 on Insider Monkey · via Yahoo Finance
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned 5.77% (net), compared to a 7.58% return for the Russell 2000 Growth Index. Despite a decline in many equity markets in January, they rebounded over the following two months, resulting in a robust 2024 first quarter. In addition, please check the fund’s top five holdings to know its best picks in 2024.
TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks like RAPT Therapeutics, Inc. (NASDAQ:RAPT), in the first quarter 2024 investor letter. RAPT Therapeutics, Inc. (NASDAQ:RAPT) is a clinical-stage immunology-based biopharmaceutical company. The one-month return of RAPT Therapeutics, Inc. (NASDAQ:RAPT) was -26.08%, and its shares lost 85.19% of their value over the last 52 weeks. On June 20, 2024, RAPT Therapeutics, Inc. (NASDAQ:RAPT) stock closed at $3.09 per share with a market capitalization of $110.983 million.